In 111 DAC

Drug Profile

In 111 DAC

Alternative Names: DTPA-adenosylcobalamin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Mayo Clinic; Naviscan PET Systems
  • Class Heavy metals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Diagnosis) in USA (Parenteral, Injection)
  • 10 Dec 2007 In 111 DAC is still in phase I trials for Diagnostic Imaging in USA
  • 01 Dec 2005 Mayo Clinic and Naviscan PET Systems have entered into licensing agreement for use of In 111 DAC as molecular imaging agent in cancer patients
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top